Hapten-Induced Primary and Memory Humoral Responses Are Inhibited by the Infusion of Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab)
- 1 February 2001
- journal article
- Published by Elsevier in Clinical Immunology
- Vol. 98 (2) , 175-179
- https://doi.org/10.1006/clim.2000.4980
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using RituximabNeurology, 1999
- Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor ClearanceJournal of Clinical Oncology, 1999
- IDEC‐C2B8 anti‐CD20 (Rituximab) immunotherapy in patients with low‐grade non‐Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patientsEuropean Journal of Haematology, 1999
- Survival of long-lived plasma cells is independent of antigen [In Process Citation]International Immunology, 1998
- Humoral Immunity Due to Long-Lived Plasma CellsImmunity, 1998
- IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1997
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994
- The ELISA-plaque assay for the detection and enumeration of antibody-secreting cells: An overviewJournal of Immunological Methods, 1986
- Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytesEuropean Journal of Immunology, 1986